Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROPHESY-2 trial
ISRCTN92114384Phase 3Recruiting
- Sponsor
- Queen Mary University of London
- Start
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial in Bleeding comparing Prothrombin complex concentrate with Fresh frozen plasma / OctaplasLG (2 arms). Primary endpoint: Composite postoperative morbidity and mortality endpoint. Started Feb 2025; status: recruiting.
02
Drugs
prothrombin complex concentrate, humanfresh-frozen plasmaoctaplas lg
03
Conditions
Bleeding
Beyond the preview
Go deeper on ISRCTN92114384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN92114384.